Apogee Therapeutics shares are down about 3% in the latest session as traders continue to price in dilution and supply from the company’s recent follow-on equity raise. The financing introduced a near-term “offering overhang” dynamic—more shares outstanding and potential incremental shares from the underwriters’ option—which can pressure prices even without new clinical news. �citeturn0search2turn0search12turn1search0turn1search3turn1search6

In late March 2026, Apogee launched and then priced an underwritten public offering around $350 million at $70 per share, with closing expected March 26, 2026, subject to customary conditions. While the cash strengthens the balance sheet for a clinical-stage biotech, the tradeoff is dilution for existing holders and added supply that can cap upside in the weeks following pricing. �citeturn1search0turn0search12turn1search3turn1search6

Follow-on offerings often create a multi-day to multi-week digestion period: deal pricing resets investor reference points, and any hedge activity or repositioning by funds can weigh on the tape even after the deal closes. With no clearly dominant new trial-data headline driving demand today, the stock’s drift lower is consistent with post-offering technical pressure and investors recalibrating valuation around a larger share count. �citeturn0search2turn0search12turn1search6

Investors are monitoring whether additional securities activity emerges from recent filings and whether management provides updated timing on 2026 pipeline catalysts. A proxy/SEC document filed on April 26, 2026 references materials dated about April 24, 2026, underscoring that corporate/filing-related updates are in focus alongside upcoming clinical milestones. �citeturn1search14